课题基金 / 基金详情

Validation of Cross-Species Biomarkers of DNA Damage

Validation of Cross-Species Biomarkers of DNA Damage
DNA 损伤跨物种生物标志物的验证
批准号:
9769037
负责人:
Jeffrey C Bemis
金额:
$61.75万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-01-15 至 2021-08-31
关键词:
AffectAgeAgingAliquotAntineoplastic AgentsBenchmarkingBiological AssayBiological MarkersBloodBlood VolumeBlood specimenBloom SyndromeBody mass indexC-reactive proteinCancer PatientCellsChromosomal BreaksCodeCongenital AbnormalityDNA DamageDNA RepairDNA Repair DisorderDataDevelopmentDiseaseDoseEnvironmental ExposureErythropoiesisEvaluationExhibitsFamily suidaeFanconi&aposs AnemiaFlow CytometryFolic AcidFrequenciesGene MutationGenesGenomic InstabilityGenotypeHematopoieticHeritabilityHumanHuman PathologyImmunomagnetic SeparationIndividualIndividual DifferencesInflammationInflammatory Bowel DiseasesIntegration Host FactorsInternationalInvestigationKineticsLaboratoriesLaboratory Animal ModelsLaboratory AnimalsLaboratory StudyMalignant NeoplasmsMeasurementMessenger RNAMonitorMusMutagensMutationNatureNewborn InfantNijmegen Breakage SyndromeObesityOccupational ExposureOperative Surgical ProceduresPatientsPerformancePharmaceutical PreparationsPharmacotherapyPhasePhenotypePhysiologicalPlatinumPlayPopulationPopulation StudyRaceRattusReportingReproducibilityResearchResearch PersonnelReticulocytesRodentRodent ModelRoleSamplingScientistSickle Cell AnemiaSmall Business Innovation Research GrantSourceSpecimenTP53 geneTestingValidationWorkarmbasechemotherapyepidemiology studygenotoxicityhuman DNA damagehuman diseasehuman studyhydroxyurealifestyle factorsmouse modelmultidisciplinarynext generationpatient populationphase 2 studypopulation basedprototyperesponsesexspecific biomarkerstemozolomidetool

项目摘要

项目成果

Jeffrey C Bemis的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 该项目将验证两种高通量的基于人类血液的DNA损伤分析,并开发它们 变成了商业工具包。这些检测方法监测与重要人类疾病相关的损害类型。 而PIG-A检测报告的是基因突变,微核网织红细胞(MN-RET)检测是 对染色体断裂和/或丢失做出反应。这些生物标志物适用于人类和 并将满足两个重要需求:将在实验室动物模型中的发现扩展到 直接在人体上进行研究,并了解受控良好的机械实验室研究的表现 最早是在人类身上观察到的。在流式细胞术之前,这些分析利用免疫磁分离来 极大地丰富了相关的细胞群体,从而提高了分析的精确度和灵敏度。通过 提供简单易用的试剂盒,具有充分记录的重复性和实验室间的可转移性; 为了验证生物标记物的具体用途,研究人员将拥有前所未有的可用工具 综合研究导致个体间差异的因素的效率 人类DNA损伤。应用包括对药物治疗、宿主和/或生活方式因素的研究 导致DNA损伤和修复的个体间差异,对反病毒的敏感性被夸大 肿瘤治疗和基于人群的环境暴露流行病学研究,包括 职业接触。该项目得益于国际上强大的多学科团队 公认的科学家,有成功地将研究进展转化为可靠的记录 商业检测试剂盒。
英文摘要
Project Summary This project will validate two high throughput human blood-based DNA damage assays and develop them into commercial kits. The assays monitor types of damage associated with important human diseases. Whereas the PIG-A assay reports on gene mutation, the micronucleated reticulocyte (MN-RET) assay is responsive to chromosomal breaks and/or losses. The biomarkers are applicable to both humans and laboratory animals and will fulfill two important needs: extension of findings in laboratory animal models to direct studies in humans, and performance of well-controlled mechanistic laboratory studies to understand observations first made in humans. The assays utilize immunomagnetic separation prior to flow cytometry to dramatically enrich the relevant cell populations and thereby enhance assay precision and sensitivity. By providing simple-to-use kits with thoroughly documented reproducibility and inter-laboratory transferability, and validating the biomarkers for specific uses, researchers will have available tools with unprecedented efficiencies for comprehensively studying those factors that contribute to inter-individual differences in human DNA damage. Applications include the study of drug treatments, host and/or life-style factors that contribute to inter-individual differences in DNA damage and repair, exaggerated sensitivities to anti- neoplastic therapies, and population-based epidemiology studies of environmental exposures, including occupational exposures. The project benefits from a strong multidisciplinary team of internationally recognized scientists with a proven track record of successfully converting research advances into reliable commercial assay kits.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1002/em.22403
发表时间: 2020-11
期刊: Environmental and molecular mutagenesis
影响因子: 2.8
作者: [Baig A, Avlasevich SL, Torous DK, Bemis JC, Saubermann LJ, Lovell DP, MacGregor JT, Dertinger SD]
通讯作者: Dertinger SD
DOI: 10.1002/em.22393
发表时间: 2020-10
期刊: Environmental and molecular mutagenesis
影响因子: 2.8
作者: [Torous DK, Avlasevich SL, Khattab MG, Baig A, Saubermann LJ, Chen Y, Bemis JC, Lovell DP, Walker VE, MacGregor JT, Dertinger SD]
通讯作者: Dertinger SD
DOI: 10.1002/em.22427
发表时间: 2021-03
期刊: Environmental and molecular mutagenesis
影响因子: 2.8
作者: [Dertinger SD, Bhalli JA, Roberts DJ, Stankowski LF Jr, Gollapudi BB, Lovell DP, Recio L, Kimoto T, Miura D, Heflich RH]
通讯作者: Heflich RH
Lack of hydroxyurea-associated mutagenesis in pediatric sickle cell disease patients.
儿童镰状细胞病患者缺乏羟基脲相关诱变。
DOI: 10.1002/em.22536
发表时间: 2023
期刊: Environmental and molecular mutagenesis
影响因子: 2.8
作者: [Torous,DorotheaK, Avlasevich,Svetlana, Bemis,JeffreyC, Howard,Thad, Ware,RussellE, Fung,Chunkit, Chen,Yuhchyau, Sahsrabudhe,Deepak, MacGregor,JamesT, Dertinger,StephenD]
通讯作者: Dertinger,StephenD
Modeling the Responsiveness of Sensitive Populations to Genotoxic Agents Using DNA Repair Inhibitors
  • 批准号:
    10734425
  • 项目类别:
  • 资助金额:
    $23.03万
  • 财政年份:
    2023
  • 负责人:
    Jeffrey C Bemis
  • 依托单位:
High Throughput Screen and High Information Follow-Up Tests for Genotoxicants
  • 批准号:
    10605311
  • 项目类别:
  • 资助金额:
    $68.25万
  • 财政年份:
    2022
  • 负责人:
    Jeffrey C Bemis
  • 依托单位:
High Throughput Screen and High Information Follow-Up Tests for Genotoxicants
  • 批准号:
    10576559
  • 项目类别:
  • 资助金额:
    $94.51万
  • 财政年份:
    2022
  • 负责人:
    Jeffrey C Bemis
  • 依托单位:
High Throughput Screen and High Information Follow-Up Tests for Genotoxicants
  • 批准号:
    10255405
  • 项目类别:
  • 资助金额:
    $20.47万
  • 财政年份:
    2021
  • 负责人:
    Jeffrey C Bemis
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: